MedTrace Logo

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)

NCT00725075 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 215

Last updated 2018-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether MK-8435 (Org 25935) is more effective than placebo in improving negative symptoms in participants with schizophrenia who are concurrently treated with a stable dose of a second generation antipsychotic.

Conditions

Interventions

DRUG

MK-8435 (Org 25935) 4-8 mg

Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day

DRUG

Placebo

Matching placebo for MK-8435 (Org 25935) administered orally BID

DRUG

MK-8435 (Org 25935) 12-16 mg

Administered orally BID for a final concentration of 24-32 mg/day

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-10
Primary Completion
2008-10-24
Completion
2008-10-24

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725075 on ClinicalTrials.gov